Abstract
To the Editor: Brown et al. (Oct. 31 issue)1 report that the International Diabetes Closed Loop (iDCL) trial showed the superiority of a closed-loop system of insulin delivery over a glucose sensor–augmented insulin pump for glycemic control in patients with type 1 diabetes. The closed-loop device has been expected to lead to stable glycemic status without frequent adjustment of insulin infusions. The unscheduled contacts (i.e., follow-up visits and telephone contacts) among patients assigned to receive treatment with a closed-loop device (the closed-loop group), however, were more frequent than among those assigned to receive treatment with a sensor-augmented pump (the control .
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
